That short window, he argued, changes the practical demands facing anti-doping authorities. Testing riders only after a stage or during daytime hours could allow certain methods to escape detection entirely. “Then you can’t test after the Plateau de Solaison, because why would you take it on a rest day?” he continued. “You have to test for it at a time when it matters.”
Naesen points towards growth hormone testing
Naesen suggested growth hormones may have been among the substances targeted during the checks, although he made clear that this was based on what he had heard rather than confirmed information from the authorities.
“I hear they’re looking for growth hormones,” he said. “Who’s ever been caught using those? This is the first time I’ve heard of a crackdown on growth hormones. That’s something that used to be undetectable and was used back in the wild days."
His comments raise a broader question for modern anti-doping programmes. If substances can be administered and cleared from the body between conventional testing windows, authorities may feel compelled to carry out controls at more disruptive times.
That does not mean Naesen supported the handling of the Pogacar and Vingegaard checks without reservation. The Belgian described the intervention by the French anti-doping authorities as potentially unprofessional and questioned why only certain leading riders were disturbed.
Questions over fairness and where to draw the line
Naesen pointed out that Pogacar and Vingegaard were reportedly woken for testing while other general classification contenders, including Remco Evenepoel and Paul Seixas, were not subjected to the same disruption. “In any case, it’s somewhat unfair that neither he nor Evenepoel were subjected to those checks,” he said when discussing Seixas.
The unequal impact on riders is central to his concern. Even when a test is permitted under the regulations and scientifically justified, waking selected competitors during the night can affect recovery and preparation before a decisive
Tour de France stage.
“You have to draw the line somewhere, because you can’t just assume it’s all part of the game,” Naesen said. “What can you put an athlete through?”
Naesen contrasted the overnight visit with his own recent experience of anti-doping testing, which he described as respectful and straightforward. “They were Belgians, very respectful people,” he recalled. “It’s a pleasant atmosphere at the table. You have a cup of coffee together, and then you have to sit for 10 minutes while they draw your blood. It’s all perfectly fine; it’s a very friendly process. But at two in the morning?”
The former Tour de France stage winner therefore stopped short of rejecting night-time controls altogether. His position was that the need to catch increasingly difficult forms of doping must be balanced against the welfare of riders and the fairness of selectively disrupting their sleep.
Naesen also refused to draw a direct link between Vingegaard’s overnight test and the crash that later ended his Tour, although he did not believe the potential effects of disturbed recovery could be dismissed entirely. “You can’t directly link the two, but you can’t completely rule it out either,” he said.
The episode has highlighted a problem likely to become more prominent as anti-doping methods evolve. If the substances being targeted are only visible for a few hours, testing may have to become more unpredictable. The challenge will be ensuring that those controls are applied consistently and with a clear justification rather than leaving riders to absorb unequal disruption during the biggest races of the season.